Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye [Ophthalmic Surg Lasers Imaging] Journal article | | Title | Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. | | Author(s) | Kahook MY, Kimura AE, Wong LJ, Ammar DA, Maycotte MA, Mandava N | | Institution | Department of Ophthalmology, Rocky Mountain Lions Eye Institute, University of Colorado at Denver, Aurora 80045, USA. | | Source | Ophthalmic Surg Lasers Imaging 2009 May-Jun; 40(3):293-5. | | MeSH | Aged
Aged, 80 and over
Angiogenesis Inhibitors
Antibodies, Monoclonal
Antihypertensive Agents
Choroidal Neovascularization
Female
Humans
Injections
Intraocular Pressure
Macular Degeneration
Male
Middle Aged
Ocular Hypertension
Retrospective Studies
Tonometry, Ocular
Vascular Endothelial Growth Factor A
Vitreous Body
| | Abstract | This retrospective case series reports sustained elevation of intraocular pressure (IOP) after single or repeated intravitreal injections of bevacizumab (Avastin; Genentech, San Francisco, CA) for wet age-related macular degeneration (AMD). All six cases experienced significant and sustained elevation in IOP after single or repeated intravitreal injections of bevacizumab. Initiation or advancement of IOP-lowering therapy was required in all cases. The results support the need for further studies investigating the incidence of this potential side effect and the need for close long-term surveillance of IOP after injection of bevacizumab, particularly in patients with glaucoma or suspected glaucoma. Future in vitro and in vivo studies are needed to better understand the reasons for this observed phenomenon. | | Language | eng | | Pub Type(s) | Case Reports
Journal Article
| | PubMed ID | 19485295 |
|
|
| |
Advertise on this site.
| | |
|
